These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 28035494

  • 1. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw.
    Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S.
    J Bone Miner Metab; 2017 Jan; 35(1):6-19. PubMed ID: 28035494
    [Abstract] [Full Text] [Related]

  • 2. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
    Shibahara T.
    Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries.
    Taguchi A, Shiraki M, Morrison A, Khan AA.
    Osteoporos Sarcopenia; 2017 Jun; 3(2):64-74. PubMed ID: 30775507
    [Abstract] [Full Text] [Related]

  • 6. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons.
    Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M.
    J Bone Miner Metab; 2010 Jul; 28(4):365-83. PubMed ID: 20333419
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Update MRONJ and perspectives of its treatment.
    Voss PJ, Poxleitner P, Schmelzeisen R, Stricker A, Semper-Hogg W.
    J Stomatol Oral Maxillofac Surg; 2017 Sep; 118(4):232-235. PubMed ID: 28697987
    [Abstract] [Full Text] [Related]

  • 9. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B, Muschitz Ch, Gruber R, Brandtner Ch, Svejda Ch, Gasser RW, Santler G, Dimai HP.
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [Abstract] [Full Text] [Related]

  • 10. Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature.
    Kanwar N, Bakr MM, Meer M, Siddiqi A.
    Br Dent J; 2020 Jun; 228(11):886-892. PubMed ID: 32541753
    [Abstract] [Full Text] [Related]

  • 11. Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan.
    Nashi M, Kishimoto H, Kobayashi M, Tachibana A, Suematsu M, Fujiwara S, Ota Y, Hashitani S, Shibatsuji T, Nishida T, Fujimura K, Furudoi S, Ishida Y, Ishii S, Fujita T, Iwai S, Shigeta T, Harada T, Miyai D, Takeda D, Akashi M, Noguchi K, Takenobu T.
    J Dent Sci; 2023 Jul; 18(3):1156-1163. PubMed ID: 37404599
    [Abstract] [Full Text] [Related]

  • 12. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.
    Sakai Y, Shindo T, Sato S, Takahashi A, Kunishima Y, Kato R, Itoh N, Okada M, Tachiki H, Taguchi K, Takayanagi A, Hotta H, Horita H, Matsukawa M, Matsuki M, Nishiyama K, Miyazaki A, Hashimoto K, Tanaka T, Masumori N.
    J Bone Miner Metab; 2021 Jul; 39(4):661-667. PubMed ID: 33704573
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.
    Okamura M, Fujita K, Yamamoto Y, Kanai O, Nakatani K, Horimoto K, Hashimoto M, Sawai S, Shimosato M, Yoshida K, Mio T.
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):380-384. PubMed ID: 32893984
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage.
    Watanabe T, Asai K, Fukuhara S, Uozumi R, Bessho K.
    PLoS One; 2021 Dec; 16(1):e0244859. PubMed ID: 33395446
    [Abstract] [Full Text] [Related]

  • 19. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs.
    Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H, American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents.
    J Am Dent Assoc; 2011 Nov; 142(11):1243-51. PubMed ID: 22041409
    [Abstract] [Full Text] [Related]

  • 20. [Bisphosphonate and denosumab-related osteonecrosis of the jaw: Epidemiology, diagnosis and management].
    Dupic G, Collangettes D, Dillies AF, Calvet L, Tournilhac O, Bay JO, Mahammedi H.
    Bull Cancer; 2015 Dec; 102(12):1010-9. PubMed ID: 26607453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.